Literature DB >> 26434380

Invasive pneumococcal disease among children younger than 5 years of age before and after introduction of pneumococcal conjugate vaccine in Casablanca, Morocco.

Idrissa Diawara1, Khalid Zerouali2, Khalid Katfy3, Bahija Zaki4, Houria Belabbes5, Jillali Najib6, Naima Elmdaghri7.   

Abstract

OBJECTIVES: The purpose of this study was to compare the incidence rate of invasive pneumococcal disease, the rates of antibiotic resistance and serotype distribution among children ≤5 years old before and after PCVs introduction in Casablanca, Morocco.
METHODS: This study was conducted at the Ibn Rochd University Hospital Centre of Casablanca during two periods encompassing pre-and post-implementation of PCVs, respectively from January 2007 to October 2010 and from January 2011 to December 2014. All the non-duplicate invasive S. pneumoniae isolates recovered during the study periods were included.
RESULTS: There were 136 cases of IPD, 91 before and 45 after PCVs introduction. The greatest decrease in incidence rate of IPD occurred in children ≤ 2 years of age declining from 34.6 to 13.5 per 100,000 populations (p<0.0001) before and after vaccination, respectively. The incidence rate of PCV-7, PCV-10 non-PCV-7 and PCV-13 non-PCV-10 serotypes decrease significantly from 18.0 to 4.6, from 5.7 to 1.3 and from 5.7 to 0.8/100,000 population (p<0.001) in the same age, respectively.
CONCLUSION: Shifts in the distribution of IPD serotypes and reductions in the incidence rate of disease suggest an effective reduction of the burden of IPD in children, but continued high quality surveillance is critical to assess the changes in serotype distributions.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; Invasive pneumococcal disease; Pneumococcal conjugate vaccine; Streptococcus pneumoniae

Mesh:

Substances:

Year:  2015        PMID: 26434380     DOI: 10.1016/j.ijid.2015.09.019

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  16 in total

1.  Streptococcus pneumoniae vaccination strategies and its expected impact on penicillin non-susceptibility in children under the age of five: Let's recap!

Authors:  Hiba Sabbar; Chafik Mahraoui; Magdalena Bastìas Garcià; Imane Jroundi
Journal:  Vaccine X       Date:  2022-05-14

2.  Pneumococci Can Become Virulent by Acquiring a New Capsule From Oral Streptococci.

Authors:  Moon H Nahm; Terry Brissac; Mogens Kilian; Jiri Vlach; Carlos J Orihuela; Jamil S Saad; Feroze Ganaie
Journal:  J Infect Dis       Date:  2020-07-06       Impact factor: 7.759

3.  A case report of parapneumonic pleural effusion caused by Streptococcus pneumoniae serotype 19A in a child immunized with 13-valent conjugate pneumococcal vaccine.

Authors:  Idrissa Diawara; Khalid Zerouali; Naima Elmdaghri; Abderrahman Abid
Journal:  BMC Pediatr       Date:  2017-04-27       Impact factor: 2.125

4.  Molecular characterization of penicillin non-susceptible Streptococcus pneumoniae isolated before and after pneumococcal conjugate vaccine implementation in Casablanca, Morocco.

Authors:  Idrissa Diawara; Abouddihaj Barguigua; Khalid Katfy; Kaotar Nayme; Houria Belabbes; Mohammed Timinouni; Khalid Zerouali; Naima Elmdaghri
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-04-04       Impact factor: 3.944

5.  Surgical wound infection caused by a multi drug resistant Streptococcus pneumoniae Serotype 19A after a total coloproctectomy with ileostomy.

Authors:  Nzoyikorera Néhémie; Khalid Zerouali; Idrissa Diawara; Khalid Katfy; Fakhreddine Maaloum; Sylvestre Kabura; Bahija Zaki; Chehab Farid; Houria Belabbes; Naima Elmdaghri
Journal:  Pan Afr Med J       Date:  2020-04-06

6.  Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium.

Authors:  Matt D Wasserman; Heather L Sings; Michele R Wilson; Maarten J Postma; Marie-Claude Breton; Cheryl McDade; Raymond A Farkouh
Journal:  Infect Dis Ther       Date:  2018-11-20

7.  Effectiveness of pneumococcal conjugate vaccines against invasive pneumococcal disease among children under five years of age in Africa: A systematic review.

Authors:  James Samwel Ngocho; Best Magoma; Gaudencia Alois Olomi; Michael Johnson Mahande; Sia Emmanueli Msuya; Marien Isaäk de Jonge; Blandina Theophil Mmbaga
Journal:  PLoS One       Date:  2019-02-19       Impact factor: 3.240

8.  [Meningitis caused by Streptococcus pneumoniae serotype 7a in an infant vaccinated with two doses of 13-valent pneumococcal conjugate vaccine: a case study].

Authors:  Kaoutar Ouazzani Touhami; Hind El Bayed Sakkali; Fakhreddine Maaloum; Idrissa Diawara; Makine Ouazzani Touhami; Mohamed Bezzari; Khalid Zerouali; Houria Belabbes
Journal:  Pan Afr Med J       Date:  2019-04-26

Review 9.  Impact of vaccination on carriage of and infection by antibiotic-resistant bacteria: a systematic review and meta-analysis.

Authors:  Li Min Wang; Tiago Cravo Oliveira Hashiguchi; Michele Cecchini
Journal:  Clin Exp Vaccine Res       Date:  2021-05-31

Review 10.  Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia.

Authors:  Auliya A Suwantika; Neily Zakiyah; Arif S W Kusuma; Rizky Abdulah; Maarten J Postma
Journal:  Vaccines (Basel)       Date:  2020-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.